{
    "eid": "2-s2.0-85020016772",
    "title": "Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in thai breast cancer patients",
    "cover-date": "2017-04-15",
    "subject-areas": [
        {
            "$": "Oncology",
            "@code": "2730"
        }
    ],
    "keywords": [
        "Cytochrome P450",
        "Endoxifen",
        "Human",
        "Pharmacogenetics",
        "Pharmacogenomics",
        "Single nucleotide polymorphisms"
    ],
    "authors": [
        "Wanaporn Charoenchokthavee"
    ],
    "citedby-count": 6,
    "ref-count": 26,
    "ref-list": [
        "PharmGKB summary: Tamoxifen pathway, pharmacokinetics",
        "Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer",
        "CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients",
        "Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer",
        "CYP2D6 Genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial",
        "Pharmacogenomics of breast cancer therapy: An update",
        "Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry",
        "Pharmacogenomics of tamoxifen: Roles of drug metabolizing enzymes and transporters",
        "Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase i and II enzymes on their concentration levels in plasma",
        "Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: Effect on active metabolite isomers and the antiestrogenic activity score",
        "Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer",
        "CYP2D6 genotype and tamoxifen activity: Understanding interstudy variability in methodological quality",
        "Tamoxifen and CYP2D6: A contradiction of data",
        "Pharmacogenomics of CYP2D6: Molecular genetics, interethnic differences and clinical importance",
        "Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients",
        "Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients",
        "Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen",
        "Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment",
        "Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients",
        "Effects of SULT1A1 copy number variation on estrogen concentration and tamoxifen-associated adverse drug reactions in premenopausal Thai breast cancer patients: A preliminary study",
        "G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences",
        "Statistical Power Analysis for the Behavioral Sciences",
        "Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: Application to a clinical study",
        "Experimental Design: Procedures for the Behavioral Sciences",
        "Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer",
        "Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "affilname": "Chulalongkorn University",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Chulalongkorn University",
        "National Research Council of Thailand"
    ]
}